Fig. 2: Baseline to posttreatment changes in inflammatory biomarkers in plasma.
From: Rapamycin treatment for Alzheimer’s disease and related dementias: a pilot phase 1 clinical trial
Baseline and post-treatment plasma biomarker (a–e) (N = 10 participants) changes were evaluated using paired samples t-tests or Wilcoxon signed rank tests. FDR-corrected p-values and color coding by participant are displayed. Mean difference from baseline to post-treatment. a INF-γ: 4.38 pg/ml; (b) IL−5: 0.33 pg/ml; (c) VEGF-D: 3741.0 pg/ml; (d) sFlt1: 258.88 pg/ml; (e) PIGF: 20.81 pg/ml. IFN‐γ interferon gamma, IL interleukin, VEGF vascular endothelial growth factor, sFLT-1 soluble fms-like tyrosine kinase, PIGF placental growth factor.
